BYK 49187
目录号 : GC14434
Potent PARP-1/PARP-2 inhibitor
Cas No.:163120-31-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
BYK 49187 is a potent inhibitor of PARP-1 and PARP-2 with pIC50 value pIC50 values of 8.36 and 7.50 for cell-free recombinant PARP-1 and murine PARP-2 respectively [1].
Poly (ADP-ribose) polymerase (PARP) is a family of proteins involved in a number of cellular processes involving mainly DNA repair and programmed cell death [1].
BYK 49187 is a potent inhibitor of human PARP and displays no selectivity for PARP1/2 [1]. PAR formation in A549, C4I, and H9c2 cells was inhibited by BYK49187 with pIC50 values of 7.80, 7.02, and 7.65, respectively. BYK 49187 displays potent inhibitory activity against human PARP-1 in cell-free and cellular assays in vitro [1].
In the test of effect of BYK 49187 on myocardial infarct size in the rat, intravenous administration of the lower dose of BYK 49187 was nearly ineffective (only 6% reduction in infarct size), whereas the higher dose (3 mg/kg followed by 3 mg/kg/h) caused a significant reduction in infarct size of 22% compared with vehicle. Blood samples of rats treated with 3 mg/kg i.v. BYK49187 significantly inhibited PARP-1 by 80% compared with sham operation [1].
References:
[1]. Eltze T, Boer R, Wagner T, et al. Imidazoquinolinone, Imidazopyridine, and Isoquinolindione Derivatives as Novel and Potent Inhibitors of the Poly(ADP-ribose) Polymerase (PARP): A Comparison with Standard PARP Inhibitors. Mol Pharmacol, 2008, 74 (6):1587–1598.
| Cas No. | 163120-31-8 | SDF | |
| 化学名 | 2-(4-(4-methyl-1H-imidazol-5-yl)piperidin-1-yl)-4H-imidazo[4,5,1-ij]quinolin-6(5H)-one | ||
| Canonical SMILES | O=C1CCN2C3=C1C=CC=C3N=C2N4CCC(C5=C(C)N=CN5)CC4 | ||
| 分子式 | C19H21N5O | 分子量 | 335.4 |
| 溶解度 | <16.77mg/ml in ethanol | 储存条件 | Store at 4°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.9815 mL | 14.9076 mL | 29.8151 mL |
| 5 mM | 0.5963 mL | 2.9815 mL | 5.963 mL |
| 10 mM | 0.2982 mL | 1.4908 mL | 2.9815 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。